EC Clears Cannabidiol for Severe Forms of Epilepsy Deborah Brauser Medscape Medical News © September 23, 2019 The European Commission (EC) has approved the add-on use of cannabidiol oral solution (Epidyolex, GW Pharmaceuticals) for treating seizures associated with two severe forms of epilepsy, the manufacturer reports. The indication for the drug in the EC's marketing authorization is for use as adjunctive therapy with clobazam (multiple brands) in patients ages 2 and older who have Lennox-Gastaut syndrome (LGS) or Dravet syndrome. As reported by Medscape Medical News, the European Medicine's Agency's (EMA's) Committee for Medicinal Products for Human Use recommended approval for the drug in July. A year earlier, [...]
Lire la suiteA National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017 Hongying Dai, Kimber P. Richter JAMA Network Open, 2019, 2, (9), e1911936. doi:10.1001/jamanetworkopen.2019.11936 Abstract IMPORTANCE : The number of states legalizing marijuana for medical and recreational use is increasing. Little is known regarding how or why adults with medical conditions use it. OBJECTIVES : To report the prevalence and patterns of marijuana use among adults with and without medical conditions, overall and by sociodemographic group, and to further examine the associations between current marijuana use and the types and number of medical conditions. DESIGN, SETTING, AND PARTICIPANTS : This survey study used a probability [...]
Lire la suiteTextes - Recueil du Bon Plant François Olivier Gagnon-Hébert 2019 Titre : Pas de panique ! Le cannabis était là avant nous… et il le sera sûrement encore après nous. Le cannabis, ce n’est pas le nom d’un poison, ni d’une drogue pharmaceutique. Ce n’est pas non plus un mot inventé par les politiciens pour faire peur ou pour influencer les résultats d’un concours de popularité à l’échelle du pays. Le cannabis peut être bien des choses pour bien des personnes, mais avant même d’être le démon incarné qui rend les mœurs légères, et avant même d’être le prochain remède holistique à tous les maux [...]
Lire la suiteAdolescent‐onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus Grace Blest‐Hopley | Aisling O'Neill | Robin Wilson | Vincent Giampietro | David Lythgoe | Alice Egerton | Sagnik Bhattacharyya Addiction Biology, 2019, e12827, 1-11. DOI: 10.1111/adb.12827 Abstract Cannabis use has been associated with adverse mental health outcomes, the neurochemical underpinnings of which are poorly understood. Although preclinical evidence suggests glutamatergic dysfunction following cannabis exposure in several brain regions including the hippocampus, evidence from human studies have been inconsistent. We investigated the effect of persistent cannabis use on the brain levels of N‐acetyl aspartate (NAA) and myo-inositol, [...]
Lire la suiteThe genus Datura L. (Solanaceae) in Mexico and Spain – Ethnobotanical perspective at the interface of medical and illicit uses Guillermo Benítez, Martí March-Salas, Alberto Villa-Kamel, Ulises Cháves-Jiménez, Javier Hernández, Nuria Montes-Osuna, Joaquín Moreno-Chocano, Paloma Cariñanos Journal of Ethnopharmacology, 2018, Volume 219, Pages 133-151. https://doi.org/10.1016/j.jep.2018.03.007 A B S T R A C T Ethnopharmacological relevance : The different species of the genus Datura have been used traditionally by some pre-Columbian civilizations, as well as in medieval rituals linked to magic and witchcraft in both Mexico and Europe. It is also noteworthy the use of different alkaloids obtained from the plants for medicinal purposes in the treatment [...]
Lire la suiteThe Consumption of Psychoactive Plants During Religious Rituals : The Roots of Common Symbols and Figures in Religions and Myths H. Umit Sayin NeuroQuantology, June 2014, Volume 12, Issue 2, 276-296 Doi : 10.14704/nq.2014.12.2.753 ABSTRACT Psychoactive plants which contain hallucinogenic molecules that induce a form of altered states of consciousness (HASC) have been widely used during the religious rituals of many cultures throughout the centuries, while the consumption of these plants for spiritual and religious purposes is as old as human history. Some of those cultures were shaman and pagan subcultures; African native religions; Bwiti Cult; South American native religions; Amazon Cultures; Central American Cultures; [...]
Lire la suiteLes psychédéliques peuvent-ils traiter l'anorexie et la dépression ? RESPADD, Actualités des Addictions, n°102, septembre 2019 Depuis son enfance, Rachael Petersen a vécu avec un sentiment de chagrin inexplicable qu'aucune pharmacothérapie ou psychothérapie n’a pu entièrement atténuer. Aussi, en 2017, elle s'est portée volontaire pour participer à un petit essai clinique à l'Université Johns Hopkins, qui testait la psilocybine, l'ingrédient actif des champignons hallucinogènes, pour le traitement de la dépression chronique. «J'étais tellement déprimée», a récemment déclaré Petersen, 29 ans. «J’ai eu l’impression que le monde m’avait abandonné, que j’avais perdu le droit d’exister sur cette planète. Vraiment, c’était comme si mes [...]
Lire la suiteMarché du cannabis thérapeutique en France : les grands acteurs étrangers dans les starting-blocks RESPADD, Actualités des Addictions n°102, septembre 2019 https://www.respadd.org/publications/veille-bibliographique/ L'expérimentation du cannabis thérapeutique en France, qui doit débuter d'ici la fin de l'année, attire de grands acteurs étrangers spécialisés qui tentent de se positionner au plus tôt sur ce marché pouvant concerner jusqu'à 2,3 millions de patients, selon le Syndicat professionnel du chanvre (SPC) français. Le lancement de cette expérimentation a été entériné en juillet par l'Agence nationale de sécurité du médicament et des produits de santé (ANSM), sur la base d'un avis rendu par un comité scientifique spécialisé temporaire (CSST) [...]
Lire la suitePriority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045 Keywords : medicinal cannabis; medical marijuana Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]
Lire la suiteHeavy cannabis use, dependence and the brain : a clinical perspective Emese Kroon, Lauren Kuhns, Eva Hoch & Janna Cousijn Addictions, 2019, 1-12. doi : 10.1111/add.14776 ABSTRACT Aims : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, cannabis use disorder (CUD) and the brain. Methods : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. Results : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]
Lire la suite